Markets:

Overview

News

Currencies

International

Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

12.72 +0.01 (+0.08%)

Streaming Delayed Price Updated: 10:05 AM EDT, Sep 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle ↗

September 29, 2022

The drug has faced two advisory committees and a delayed review date.

Via Investor's Business Daily

Biohaven's ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months ↗

September 29, 2022

Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN) announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).

Via Benzinga

Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test ↗

September 29, 2022

Patients didn't show any improvements in a study meant to test multiple drugs.

Via Investor's Business Daily

Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Rise Above Previous 52-Week High

September 27, 2022

Via Investor Brand Network

Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Exceed 52-Week High

September 26, 2022

Via Investor Brand Network

Stocks That Hit 52-Week Highs On Friday ↗

September 23, 2022

On Friday, 5 companies hit new 52-week highs.

Via Benzinga

Recap: Biohaven Pharma Hldgs Q2 Earnings ↗

August 05, 2022

Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study ↗

May 23, 2022

Via Benzinga

Watch for Continued Gains in Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

September 23, 2022

Via Investor Brand Network

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

Is Viatris Inc. a Contrarian Dividend Option for Your Portfolio?

September 03, 2022

Does kicking against market trends make you even more excited about investing? If so, you may want to consider drugmaker Viatris Inc. (NASDAQ: VTRS), which produces products that treat diabetes,...

Via MarketBeat

Biohaven Pharmaceutical's Return On Capital Employed Overview ↗

August 26, 2022

Benzinga Pro data, Biohaven Pharmaceutical (NYSE:BHVN) reported Q2 sales of $215.08 million. Earnings fell to a loss of $441.88 million, resulting in a 278.01% decrease from last quarter.

Via Benzinga

$5.6 Million Bet On This Healthcare Stock? 3 Stocks Insiders Are Buying ↗

August 23, 2022

Although US stocks closed sharply lower on Monday, there were a few notable insider trades.

Via Benzinga

Freedom Biosciences Gets $10.5M In Seed Financing For Psychedelics Research, This Is What We Know ↗

August 23, 2022

Freedom Biosciences achieved a major $10.5 million in a seed financing round in which MBX Capital, PsyMed Ventures, Village Global and The Yale Startup, among others, participated.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022 ↗

August 19, 2022

Upgrades

Via Benzinga

Why These Pfizer Analysts Like The Global Blood Therapeutics Deal ↗

August 08, 2022

Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗

August 08, 2022

Via Benzinga

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗

August 05, 2022

Shares of Pfizer's rumored takeover target have rocketed for two days running.

Via Investor's Business Daily

The 3 Best Market Sectors for the Second Half of 2022 ↗

July 27, 2022

Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into.

Via InvestorPlace

Which Coronavirus Stock Could Fetch Higher Returns? ↗

July 11, 2022

This article will compare Pfizer, Moderna, and Novavax to see which of these coronavirus stocks will yield the highest returns.

Via InvestorPlace

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial

July 06, 2022

From Global Coalition for Adaptive Research

Via Business Wire

Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit? ↗

July 05, 2022

The FDA's advisors recently backed Pfizer's Covid shot for young children.

Via Investor's Business Daily

Hopeful Golden Cross Forms On Biohaven Pharma Hldgs's Chart ↗

June 23, 2022

If history is any guide, there may be good fortune ahead for shares of Biohaven Pharma Hldgs (NYSE:BHVN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish...

Via Benzinga

Looking Into Biohaven Pharmaceutical's Return On Capital Employed ↗

June 10, 2022

According to data from Benzinga Pro, during Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $318.85 million. Despite a 41.43% increase in earnings, the company posted a loss of $116.90...

Via Benzinga

3 Biotech Stocks to Buy Before They Boom ↗

June 01, 2022

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

Via InvestorPlace

Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way ↗

May 24, 2022

The company is planning to soon ask for FDA approval of etrasimod in ulcerative colitis.

Via Investor's Business Daily

BIOHAVEN INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN

May 17, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗

May 16, 2022

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...

Via Benzinga

Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review ↗

May 13, 2022

Elon Musk put his Twitter deal "on hold" but says he's "still committed" to it.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022 ↗

May 11, 2022

Upgrades

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.